Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Arrow Japan to Diversify Business from Critical Care Products
November 18, 2002
-
ARCHIVE Terumo: Sales Up 3.4% in Japan, 8.1% Overseas
November 18, 2002
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
November 18, 2002
-
ARCHIVE OTC NEWS IN BRIEF
November 18, 2002
-
ARCHIVE Kowa to Codevelop Arteriosclerosis Drugs with GENFIT of France
November 18, 2002
-
ARCHIVE MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 18, 2002
-
ARCHIVE Market Must Be Attractive to Invite Investment from Abroad: JPMA President
November 18, 2002
-
ARCHIVE REGULATORY NEWS IN BRIEF
November 18, 2002
-
ARCHIVE Yamanouchi: Record-high Sales, Operating Profits Attributable to Harnal, Lipitor
November 18, 2002
-
ARCHIVE Bill for Law on IP Presented to Lower House
November 18, 2002
-
ARCHIVE Eisai: Pariet, Aricept Contribute to Good Sales, Profits
November 18, 2002
-
ARCHIVE Drug Substitution by Pharmacists to Become Major Topic
November 18, 2002
-
ARCHIVE Semi-annual Business Results
November 18, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
November 18, 2002
-
ARCHIVE Health Minister Determines to Set Up Better Healthcare System
November 11, 2002
-
ARCHIVE Kuraya Sanseido Takes Over OTC Business from Heisei Yakuhin
November 11, 2002
-
ARCHIVE Korosho to Prepare Comprehensive GL for Clinical Trials
November 11, 2002
-
ARCHIVE Council to Issue Supplements QC Verification Seals
November 11, 2002
-
ARCHIVE Dear-Doctor Letter for Edaravone Issued
November 11, 2002
-
ARCHIVE BD Places Great Importance on Social Contribution: President Cohen
November 11, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…